Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY **PATENT APPLICATION TRANSMITTAL**

16721-0260 (42526 -Attorney Docket No. Inventors Jean-Claude Yvin, Edouard Panak, Vaclav Vetvicka Therapeutical Combination Against Cancer

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))						우
Only for new homprovisional applications under 37 to	D.F.R. 1.55(D))	Express Mail	Label No.	EV 334684165 U	JS	<u> </u>
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent applie		TO:	RESS	Mailstop Pa P.O. Box 14 Alexandria, \	ner for Patents atent Application 50 VA 22313-1450 ate, large table or	7548 U.S
Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure Drawing(s) (35 U.S.C.113) [Total Sheets] Drawing(s) (35 U.S.C.113) [Total Pages] Newly executed (original or copy) Description of Invention (37 CFR 1.63 (d)) (for a continuation/divisional with Box 18 completed) Delection of Inventor(s) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). Application Data Sheet. See 37 CFR 1.76		Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a.				
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,						
or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) of prior application No:/ Prior application information: Examiner Group / Art Unit: Recite complete dependency back to first parent application: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.						
17. CORRESPONDENCE ADDRESS						
□ Customer Number 23370						
Name (Print/Type) John K. McDonald,	Ph.D.	Registrati	on No. (Atto	orney/Agent)	42,860	
Signature XX	M Down	W.		Date	October 30, 2003	
1	<i>f</i>		_			